CA2028848A1 - Formulations de peptides lyophilises - Google Patents

Formulations de peptides lyophilises

Info

Publication number
CA2028848A1
CA2028848A1 CA002028848A CA2028848A CA2028848A1 CA 2028848 A1 CA2028848 A1 CA 2028848A1 CA 002028848 A CA002028848 A CA 002028848A CA 2028848 A CA2028848 A CA 2028848A CA 2028848 A1 CA2028848 A1 CA 2028848A1
Authority
CA
Canada
Prior art keywords
peptide
raffinose
amino acid
lyophilized
lyophilization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002028848A
Other languages
English (en)
Inventor
Tapan Audhya
Gideon Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunobiology Research Institute Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2028848A1 publication Critical patent/CA2028848A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002028848A 1989-04-11 1990-04-09 Formulations de peptides lyophilises Abandoned CA2028848A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33623689A 1989-04-11 1989-04-11
US07/336,236 1989-04-11

Publications (1)

Publication Number Publication Date
CA2028848A1 true CA2028848A1 (fr) 1990-10-12

Family

ID=23315165

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002028848A Abandoned CA2028848A1 (fr) 1989-04-11 1990-04-09 Formulations de peptides lyophilises

Country Status (5)

Country Link
EP (1) EP0420964A4 (fr)
JP (1) JPH03505334A (fr)
CA (1) CA2028848A1 (fr)
PT (1) PT93744A (fr)
WO (1) WO1990012029A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541116A (en) * 1991-09-30 1996-07-30 B.R.A.H.M.S. Diagnostica Gmbh Method for the stabilization of endogenous, physiologically active peptides
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
DE60034445T2 (de) * 1999-05-31 2008-01-03 Mitsubishi Chemical Corp. Gefriergetrocknete hgf-präparationen
KR100400541B1 (ko) * 2000-12-28 2003-10-08 엘지전자 주식회사 광자기 기록장치
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN1771080B (zh) 2003-04-08 2010-12-15 诺沃挪第克公司 包括至少一个色谱处理步骤的生产治疗用多肽或其前体的方法
WO2004089985A1 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Compositions pharmaceutiques stables
PL2328601T3 (pl) 2008-08-15 2020-07-13 Ironwood Pharmaceuticals, Inc. Formulacje zawierające linaklotyd do podawania doustnego
WO2011017502A2 (fr) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprenant du linaclotide
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
SI2603232T1 (sl) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals, Inc. Stabilne formulacije linaklotida
JP6312592B2 (ja) 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化器疾患の治療
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
CN114111232B (zh) * 2021-12-27 2024-06-25 山东新华医疗器械股份有限公司 一种冻干机控温系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000256A (en) * 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
US4190646A (en) * 1975-11-11 1980-02-26 Sloan-Kettering Institute For Cancer Research Polypeptide compositions and methods
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
US4764463A (en) * 1986-10-30 1988-08-16 The University Of Tennessee Research Corporation Platelet cyropreservation

Also Published As

Publication number Publication date
EP0420964A1 (fr) 1991-04-10
WO1990012029A1 (fr) 1990-10-18
EP0420964A4 (en) 1991-09-25
JPH03505334A (ja) 1991-11-21
PT93744A (pt) 1990-11-20

Similar Documents

Publication Publication Date Title
US6730328B2 (en) Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity
CA2028848A1 (fr) Formulations de peptides lyophilises
US5919443A (en) Stable lyophilized pharmaceutical preparations of G-CSF
US5081156A (en) Sustained-release preparation
US6250469B1 (en) Formulations for protection of peg-interferon alpha conjugates
JP3530300B2 (ja) 安定なトランスグルタミナーゼ製剤およびそれらを製造する方法
EP0420649A2 (fr) Formulations aqueuses stabilisées à base de petits peptides
SG175580A1 (en) Method of drug delivery for bone anabolic protein
EP1066059B1 (fr) Formulations servant a proteger des conjugues de peg et d'alpha-interferon
WO2000072873A1 (fr) Preparations lyophilisees de hgf
EP0804223B1 (fr) Compositions pharmaceutiques renfermant l'hch
CA2087430A1 (fr) Compositions pharmaceutiques stables contenant un facteur de croissance des fibroblastes
US5140010A (en) Stabilized aqueous formulations of thymopentin
IL147413A (en) Pharmaceutical preparations containing GRF
JPS61137828A (ja) γ−インタ−フエロン製剤組成物
MXPA03008545A (es) Composiciones farmaceuticas que contienen la hormona humana del crecimiento.

Legal Events

Date Code Title Description
FZDE Dead